Regulation of glucose metabolism in T cells: New insight into the role of phosphoinositide 3-kinases

Frontiers in Immunology

Volumn 3, Issue AUG, 2012, Pages

  Finlay, David K ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Aerobic glycolysis; C Myc; Glucose metabolism,Akt,T lymphocyte; Pdk1; Pi3k

Indexed keywords

EID: 84870173435     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00247     Document Type: Review

References (71)

1. Alessi, D.R., and Cohen,P. (1998) Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 8,55-62.
2. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I., Arthur, J. S., Alessi, D. R., and Cohen, P. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315.
3. Bayascas, J. R., Wullschleger, S., Sakamoto,K.,Garcia-Martinez,J.M., Clacher, C., Komander, D., van Aalten, D. M. F., Boini, K. M., Lang, F., Lipina, C., Logie, L., Sutherland, C., Chudek, J. A., van Diepen, J. A., Voshol, P. J., Lucocq, J. M., and Alessi, D. R. (2008). Mutation of the PDK1 PH domain inhibits protein kinaseB/Akt,leadingtosmallsizeand insulin resistance. Mol. Cell. Biol. 28, 3258-3272.
4. Brand, K., Williams, J. F., and Weidemann, M. J. (1984). Glucose and glutamine metabolism in rat thymocytes. Biochem. J. 221, 471-475.
5. Brunet, A., Park, J., Tran, H., Hu, L. S., Hemmings,B. A.,and Greenberg,M. E. (2001). Protein kinase SGK mediatessurvivalsignalsbyphosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 21,952-965.
6. Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J. C., and Abraham, R. T. (1996). Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors,wortmannin and LY294002. EMBO J. 15, 52565267.
7. Burgering, B. M. T. (2008). A brief introductiontoFOXOlogy. Oncogene 27,2258-2262.
8. Calleja,V.,Alcor,D.,Laguerre,M.,Park, J., Vojnovic, B., Hemmings, B. A., Downward, J., Parker, P. J., and Larijani, B. (2007). Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol. 5, e95. doi: 10.1371/journal.pbio.0050095
9. Cameron, A. J., De Rycker, M., Calleja, V., Alcor, D., Kjaer, S., Kostelecky, B., Saurin, A., Faisal, A., Laguerre, M., Hemmings, B. A., McDonald, N., Larijani, B., and Parker, P. J. (2007). Protein kinases, from B to C. Biochem. Soc. Trans. 35,1013-1017.
10. Cham, C. M., Driessens, G., O'Keefe, J. P., and Gajewski, T. F. (2008). Glucosedeprivationinhibitsmultiplekey gene expression events and effector functions in CD8 + T cells. Eur. J. Immunol. 38, 2438-2450.
11. Ciofani, M., and Zuniga-Pflucker, J. C. (2005). Notch promotes survival of pre-T cells at the beta-selectioncheckpoint by regulating cellular metabolism. Nat. Immunol. 6, 881-888.
12. Coffer, P. J., and Burgering, B. M. (2004). Forkhead-box transcription factors and their role in the immune system. Nat. Rev. Immunol. 4, 889-899.
13. Cornish, G. H., Sinclair, L. V., and Cantrell, D. A. (2006). Differ-ential regulation of T-cell growth by IL-2 and IL-15. Blood 108, 600-608.
14. Costello, P. S., Gallagher, M., and Cantrell, D. A. (2002). Sustained and dynamic inositol lipid metabolism inside and outside the immunologi-cal synapse. Nat. Immunol. 3, 1082-1089.
15. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000). Specificity and mechanism of action of some com-monlyusedproteinkinaseinhibitors. Biochem. J. 351,95-105.
16. Delgoffe, G. M., and Powell, J. D. (2009). mTOR: taking cues from the immune microenviron-ment. Immunology 127, 459-465.
17. Dose, M., Khan, I., Guo, Z., Koval-ovsky, D., Krueger, A., von Boehmer, H., Khazaie, K., and Gounari, F. (2006). c-Myc mediates pre-TCR-induced proliferation but not devel-opmental progression. Blood 108, 2669-2677.
18. Doughty, C. A., Bleiman, B. F., Wag-ner, D. J., Dufort, F. J., Mataraza, J. M., Roberts, M. F., and Chiles, T. C. (2006). Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidyli-nositol 3-kinase signaling in the gly-colytic control of growth. Blood 107, 4458-4465.
19. Duvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S.,Vander Heiden, M. G., MacKeigan, J. P., Finan, P. M., Clish, C.B.,Murphy,L.O.,andManning,B. D. (2010). Activation of a metabolic generegulatorynetworkdownstream of mTOR complex 1. Mol. Cell 39, 171-183.
20. Fayard, E., Gill, J., Paolino, M., Hynx, D., Hollander, G. A., and Hem-mings, B. A. (2007). Deletion of PKBalpha/Akt1 affects thymic devel-opment. PLoS ONE 2, e992. doi: 10.1371/journal.pone.0000992
21. Finlay, D., and Cantrell, D. (2010). Phosphoinositide 3-kinase and the mammalian target of rapamycin pathways control T cell migra-tion. Ann. N. Y. Acad. Sci. 1183, 149-157.
22. Finlay,D. K.,Kelly,A. P.,Clarke,R.,Sin-clair, L. V., Deak, M., Alessi, D. R., and Cantrell, D. A. (2010). Tempo-ral differences in the dependency on phosphoinositide-dependent kinase 1 distinguish the development of invariant Valpha14 NKT cells and conventionalTcells. J.Immunol. 185, 5973-5982.
23. Finlay, D. K., Sinclair, L. V., Feijoo, C., Waugh, C. M., Hagenbeek, T. J., Spits, H., and Cantrell, D. A. (2009). Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lym-phocytes. J. Exp. Med. 206, 2441-2454.
24. Fox, C. J., Hammerman, P. S., and Thompson, C. B. (2005a). Fuel feeds function: energy metabolism and the T-cell response. Nat. Rev. Immunol. 5, 844-852.
25. Fox, C. J., Hammerman, P. S., and Thompson, C. B. (2005b). The Pim kinases control rapamycin-resistantT cell survival and activation. J. Exp. Med. 201,259-266.
26. Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., Elstrom, R. L., June, C. H.,andThompson,C.B. (2002). The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769-777.
27. Garcon, F., Patton, D. T., Emery, J. L., Hirsch, E., Rottapel, R., Sasaki, T., and Okkenhaug, K. (2007). CD28 provides T-cell costimulation and enhancesPI3Kactivityattheimmune synapse independently of its capac-ity to interact with the p85/p110 heterodimer. Blood 111,1464-1471.
28. Greiner,E. F.,Guppy,M.,and Brand,K. (1994). Glucose is essential for pro-liferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J. Biol. Chem. 269, 31484-31490.
29. Grumont, R. J., Strasser, A., and Gerondakis, S. (2002). B cell growth is controlled by phosphatidylinoso-tol 3-kinase-dependent induction of Rel/NF-kappaB regulated c-myc transcription. Mol. Cell 10, 1283-1294.
30. Hagenbeek, T. J., and Spits, H. (2008). T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia 22, 608-619.
31. Hanada,M.,Feng,J.,andHemmings,B. A. (2004). Structure, regulation and functionof PKB/AKT-amajorther-apeutic target. Biochim. Biophys.Acta 1697,3-16.
32. Harriague, J., and Bismuth, G. (2002). Imaging antigen-induced PI3K acti-vation in T cells. Nat. Immunol. 3, 1090-1096.
33. Hinton,H.J.,Alessi,D.R.,andCantrell, D. A. (2004). The serine kinase phosphoinositide-dependent kinase 1 (PDK1) regulates T cell develop-ment. Nat. Immunol. 5,539-545.
34. Huppa, J. B., Gleimer, M., Sumen, C., andDavis,M.M. (2003).Continuous T cell receptor signaling required for synapsemaintenanceandfulleffector potential. Nat. Immunol. 4,749-755.
35. Iritani, B. M., Delrow, J., Grandori, C., Gomez,I.,Klacking,M.,Carlos,L. S., and Eisenman, R. N. (2002). Modu-lationof T-lymphocytedevelopment, growthandcellsizebytheMycantag-onist and transcriptional repressor Mad1. EMBO J. 21,4820-4830.
36. Jacobs, S. R., Herman, C. E., Maciver, N. J., Wofford, J. A., Wieman, H. L., Hammen, J. J., and Rathmell, J. C. (2008). Glucose uptake is limit-ing in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol. 180,4476-4486.
37. Janas, M. L., Varano, G., Gudmunds-son, K., Noda, M., Nagasawa, T., and Turner, M. (2010). Thymic develop-ment beyond beta-selection requires phosphatidylinositol 3-kinase activa-tion by CXCR4. J. Exp. Med. 207, 247-261.
38. Jarmin, S. J., David, R., Ma, L., Chai, J. G., Dewchand, H., Takesono, A., Ridley, A. J., Okkenhaug, K., and Marelli-Berg, F. M. (2008). T cell receptor-induced phosphoinositide-3-kinase p110delta activity is required for T cell localization to antigenic tissue in mice. J. Clin. Invest. 118,1154-1164.
39. Ji, H., Rintelen, F., Waltzinger, C., Bertschy Meier, D., Bilancio, A., Pearce, W., Hirsch, E., Wymann, M. P., Ruckle, T., Camps, M., Vanhae-sebroeck, B., Okkenhaug, K., and Rommel, C. (2007). Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes mul-tiple organ inflammation. Blood 110, 2940-2947.
40. Juntilla, M. M., Wofford, J. A., Birn-baum, M. J., Rathmell, J. C., and Koretzky, G. A. (2007). Akt1 and Akt2 are required for alphabeta thy-mocyte survival and differentiation. Proc. Natl. Acad. Sci. U.S.A. 104, 12105-12110.
41. Kelly, A. P., Finlay, D. K., Hinton, H. J., Clarke, R. G., Fiorini, E., Radtke, F., and Cantrell, D. A. (2007). Notch-induced T cell development requires phosphoinositide-dependent kinase 1. EMBO J. 26,3441-3450.
42. Koyasu, S. (2003). The role of PI3K in immune cells. Nat. Immunol. 4, 313-319.
43. Laplante, M., and Sabatini, D. M. (2009). mTOR signaling at a glance. J. Cell. Sci. 122, 3589-3594.
44. Lo, B. K., Yu, M., Zloty, D., Cowan, B., Shapiro, J., and McElwee, K. J. (2010). CXCR3/ligands are signifi-cantly involved in the tumorigene-sis of basal cell carcinomas. Am. J. Pathol. 176,2435-2446.
45. Macintyre,A. N.,Finlay,D.,Preston,G., Sinclair, L. V., Waugh, C. M., Tamas, P., Feijoo, C., Okkenhaug, K., and Cantrell, D. A. (2011). Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 34, 224-236.
46. Manning, B. D., and Cantley, L. C. (2007). AKT/PKB signaling: navi-gating downstream. Cell 129, 1261-1274.
47. Mao, C., Tili, E. G., Dose, M., Haks, M. C., Bear, S. E., Maroulakou, I., Horie, K., Gaitanaris, G. A., Fidanza, V., Ludwig, T., Wiest, D. L., Gounari, F.,and Tsichlis,P. N. (2007). Unequalcontribution of Akt isoforms in the double-negative to double-positive thymocyte transition. J. Immunol. 178,5443-5453.
48. Marko, A. J., Miller, R. A., Kelman, A., and Frauwirth, K. A. (2010). Induc-tion of glucose metabolism in stim-ulated T lymphocytes is regulated by mitogen-activated proteinkinase sig-naling. PLoS ONE 5, e15425. doi: 10.1371/journal.pone.0015425
49. Martin, A. L., Schwartz, M. D., Jame-son, S. C., and Shimizu, Y. (2008). Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. J. Immunol. 180,2081-2088.
50. Okkenhaug, K., Bilancio, A., Far-jot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., Smith, A. J., and Vanhaesebroeck, B. (2002). Impaired B and T cell anti-gen receptor signaling in p110delta PI3-kinasemutantmice.Science 297, 1031-1034.
51. Okkenhaug, K., Patton, D. T., Bilan-cio, A., Garcon, F., Rowan, W. C., and Vanhaesebroeck, B. (2006). The p110delta isoform of phosphoinosi-tide 3-kinase controls clonal expan-sion and differentiation of Th cells. J. Immunol. 177,5122-5128.
52. Okkenhaug,K.,andVanhaesebroeck,B. (2003). PI3K in lymphocyte develop-ment, differentiation and activation. Nat. Rev. Immunol. 3,317-330.
53. Pearce, L. R., Komander, D., and Alessi, D. R. (2010). The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 11, 9-22.
54. Reif, K., Okkenhaug, K., Sasaki, T., Pen-ninger, J. M., Vanhaesebroeck, B., and Cyster, J. G. (2004). Cutting edge: differential roles for phospho-inositide 3-kinases, p110gamma and p110delta, in lymphocyte chemo-taxis and homing. J. Immunol. 173, 2236-2240.
55. Sapkota,G. P.,Cummings,L.,Newell,F. S., Armstrong, C., Bain, J., Frodin, M., Grauert, M., Hoffmann, M., Schnapp, G., Steegmaier, M., Cohen, P.,andAlessi,D. R. (2007). BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem. J. 401, 29-38.
56. Sasaki, T., Irie-Sasaki, J., Jones, R. G., Oliveira-dos-Santos, A. J., Stanford, W.L.,Bolon,B.,Wakeham,A.,Itie,A., Bouchard, D., Kozieradzki, I., Joza, N., Mak, T. W., Ohashi, P. S., Suzuki, A.,andPenninger,J.M. (2000).Func-tion of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040-1046.
57. Shi, L. Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D. R., and Chi, H. (2011). HIF1alpha-dependentglycolyticpathwayorches-trates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208, 1367-1376.
58. Sinclair, L. V., Finlay, D., Feijoo, C., Cornish, G. H., Gray, A., Ager, A., Okkenhaug, K., Hagen-beek, T. J., Spits, H., and Cantrell, D. A. (2008). Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lympho-cyte trafficking. Nat. Immunol. 9, 513-521.
59. Smith, L. D., Hickman, E. S., Parry, R. V., Westwick, J., and Ward, S. G. (2007). PI3Kgamma is the dom-inant isoform involved in migra-tory responses of human T lym-phocytes: effects of ex vivo mainte-nance and limitations of non-viral delivery of siRNA. Cell. Signal. 19, 2528-2539.
60. Suzuki, A., Yamaguchi, M. T., Ohteki, T., Sasaki, T., Kaisho, T., Kimura, Y., Yoshida, R., Wakeham, A., Higuchi, T., Fukumoto, M., Tsubata, T., Ohashi, P. S., Koyasu, S., Penninger, J. M., Nakano, T., and Mak, T. W. (2001). T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14, 523-534.
61. Swat, W., Montgrain, V., Doggett, T. A., Douangpanya, J., Puri, K.,Vermi,W., and Diacovo, T. G. (2006). Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival. Blood 107, 2415-2422.
62. Thomas, M. S., Mitchell, J. S., DeNucci, C. C., Martin, A. L., and Shimizu, Y. (2008). The p110gamma isoform of phosphatidylinositol 3-kinase reg-ulates migration of effector CD4 T lymphocytes into peripheral inflam-matory sites. J. Leukoc. Biol. 84, 814-823.
63. Trumpp, A., Refaeli, Y., Oskarsson, T., Gasser, S., Murphy, M., Martin, G. R., and Bishop, J. M. (2001). c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 414, 768-773.
64. Vander Heiden, M. G., Cantley, L. C., and Thompson,C. B. (2009). Under-standing the Warburg effect: the metabolic requirements of cell pro-liferation. Science 324, 1029-1033.
65. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., and Bilanges, B. (2010). The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11,329-341.
66. Wang, R., Dillon, C. P., Shi, L. Z., Milasta, S., Carter, R., Finkel-stein, D., McCormick, L. L., Fitzger-ald, P., Chi, H., Munger, J., and Green, D. R. (2011). Thetranscription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871-882.
67. Waugh, C., Sinclair, L., Finlay, D., Bayascas, J. R., and Cantrell, D. (2009). Phosphoinositide (3,4,5)-triphosphate binding to phosphoinositide-dependent kinase 1 regulates a protein kinase B/Akt signaling threshold that dictates T-cell migration, not proliferation. Mol. Cell. Biol. 29,5952-5962.
68. Webb, L. M., Vigorito, E., Wymann, M. P., Hirsch, E., and Turner, M. (2005). Cutting edge: T cell develop-mentrequiresthecombinedactivities of the p110gamma and p110delta catalytic isoforms of phosphatidyli-nositol 3-kinase. J. Immunol. 175, 2783-2787.
69. Wofford, J. A., Wieman, H. L., Jacobs, S. R., Zhao, Y., and Rathmell, J. C. (2008). IL-7 promotes Glut1 traffick-ing and glucose uptake via STAT5-mediatedactivationofAkttosupport T-cell survival. Blood 111, 2101-2111.
70. Zhang, H. H., Lipovsky, A. I., Dib-ble, C. C., Sahin, M., and Man-ning, B. D. (2006). S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol. Cell 24, 185-197.
71. Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D.,Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., Duggan, M. E., and Lindsley, C. W. (2005). Discovery of 2,3,5-trisubstituted pyridine deriva-tives as potent Akt1 and Akt2 dual inhibitors. Bioorg. Med. Chem. Lett. 15, 905-909.